Panaxia and Rafa sign a collaboration agreement with PlantEXT

Panaxia Pharmaceutical Industries Israel and pharmaceutical company Rafa have announced the signing of a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company.

According to the agreement, the parties will jointly develop the next generation of medical cannabis products for patients with inflammatory bowel disease and authorized to receive medical cannabis treatment. The treatment consists of cannabis suppositories for medical use, which contain an exclusive composition based on a combination of defined and precise active ingredients of the cannabis plant. The novelty lies in the fact that, for the first time, a medical marijuana product will be developed to offer a targeted solution to patients with Crohn's disease and colitis, in order to reduce the level of inflammation in the intestine.

Inflammatory bowel diseases (Crohn's disease or ulcerative colitis) are chronic diseases that can occur at any age. For the first time now, the medical cannabis treatment of these patients will be administered with the help of an accepted conventional pharmaceutical delivery system, based on clinical research. This will offer a potential solution and increase the accessibility of treatment to more patients who need it and are eligible to receive it.

According to Dadi Segal, CEO of Panaxia, "Panaxia has already gained a proven and successful experience of cannabis suppositories in the US market." The agreement signed today constitutes a further step in the revolution in the US. accessibility to medical cannabis, also in Israel By facilitating access to cannabis through traditional pharmaceutical delivery systems, and not based on smoking, we strive to enable patients eligible for medical cannabis treatment, for a wide range of diseases, to benefit from its unique attributes, subject at all times to the advice of a qualified physician. "

According to Professor Hinanit Koltai, a leading researcher at PlantEXT and at the Volcani Institute, the Israeli agricultural research organization, whose research helped create the formulation included in the treatment: "Active ingredients should be identified and separated from the cannabis plant for the treatment of each substance.In the case of patients with inflammatory bowel disease, it is necessary to find the active pharmaceutical ingredients (API) of the plant, which are the most active compositions cannabis that may significantly reduce inflammation of the colon, the designated place of action, for example by using suppositories. "

The active ingredients contained in rectal cannabis suppositories are rapidly absorbed by the many blood vessels and are not first metabolized by the liver, in contrast to the drugs administered orally. As a consequence, the biological availability of the active ingredients increases on the one hand and a rapid physical reaction occurs on the other.